1-4 of 4
Jared Gollob, PhD MD
Close
Sort by
Journal Articles

Targeting MYD88-Mutant DLBCL with IRAKIMiDs: A Comparison to IRAK4 Kinase Inhibition and Evaluation of Synergy with Rational Combinations

Jennifer Kimberly Lue, MD, John S Manavalan, MD, Christine Klaus, BS, Rahul Kanik, PhD, Andre M. Grilo, PhD, Alice McDonald, PhD, Jared Gollob, PhD MD, Duncan Walker, PhD, Owen A. O'Connor, MD PhD, Nello Mainolfi, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 12.
https://doi.org/10.1182/blood-2020-135898
Published: 2020
Journal Articles

Ktx-120, a Novel Irakimid Degrader of IRAK4 and IMiD Substrates Shows Preferential Activity and Induces Regressions in MYD88-Mutant DLBCL CDX and PDX Models

Duncan Walker, PhD, Michele Mayo, Christine Klaus, BS, Dapeng Chen, PhD, Samyabrata Bhaduri, PhD, Kirti Sharma, Scott Rusin, Alice McDonald, PhD, Jared Gollob, PhD MD, Nello Mainolfi, PhD, Matt Weiss, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 41.
https://doi.org/10.1182/blood-2020-137750
Published: 2020
Journal Articles

Mechanisms of the Anti-Tumor Activity of STAT3 Degraders in Lymphoma

Haojing Rong, PhD, Kirti Sharma, Fred Csibi, Bin Yang, Scott Rusin, Yatao Shi, PhD, Joyoti Dey, PhD, Rahul Karnik, Michele Mayo, Karen Yuan, Yogesh Chutake, Alice McDonald, PhD, Sean Zhu, PhD, Nan Ji, PhD, Phillip Liu, PhD, Henry Li, PhD, Duncan Walker, PhD, Jared Gollob, PhD MD, Nello Mainolfi, PhD, Chris Desavi
Journal: Blood
Blood (2020) 136 (Supplement 1): 42.
https://doi.org/10.1182/blood-2020-137778
Published: 2020
Journal Articles

Small Molecule-Induced, Selective STAT3 Degradation Leads to Anti-Tumor Activity in STAT3-Dependent Heme Malignancies

Fred Csibi, Nan Ji, PhD, Bin Yang, Karen Yuan, Michele Mayo, Haojing Rong, PhD, Scott Rusin, Kirti Sharma, Christine Loh, PhD, Henry Li, PhD, Sharon Townson, Jesse Chen, PhD, Hari Kamadurai, PhD, Duncan Walker, PhD, Jared Gollob, PhD MD, Nello Mainolfi, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3803.
https://doi.org/10.1182/blood-2019-128981
Published: 2019